(VIANEWS) – The Market ended the session with GENSIGHT BIOLOGICS (SIGHT.PA) rising 11.57% to €0.96 on Monday, after two successive sessions in a row of gains. CAC 40 dropped 1.01% to €7,314.05, following the last session’s upward trend on what was an all-around negative trend trading session today.
About GENSIGHT BIOLOGICS
GenSight Biologics S.A., a clinical-stage biotechnology company, discovers, develops, and commercializes therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated ND4 gene; and GS030, which is in Phase I/II clinical trial for the treatment of retinitis pigmentosa, as well as in preclinical stage to treat dry age-related macular degeneration. The company is also developing products that are in preclinical stage targeting ophthalmic and neurodegenerative diseases. The company was incorporated in 2012 and is headquartered in Paris, France.
Earnings Per Share
As for profitability, GENSIGHT BIOLOGICS has a trailing twelve months EPS of €-0.69.
More news about GENSIGHT BIOLOGICS (SIGHT.PA).
